Cardiff Oncology, Inc. (CRDF)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.90
- As of
Kresmion compiles this page from CRDF's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Cardiff Oncology, Inc. (CRDF): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-27.
See the full CRDF dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CRDF on one page. Preview it with sample data, then open it live with a free account.
Preview the CRDF dossierActive events for CRDF
- high13F: funds reduced
3 tracked funds reduced CRDF this 2026Q2, institutional consensus
- mediumEarnings above estimates
Q2-2026: Beat consensus by 14.9%, EPS $-0.14 vs $-0.1645 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 62% of CRDF (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +434% to CRDF (2026Q2)
- medium13F: new position
Point72 Asset Management, L.P. new position in CRDF
FREE, NO ACCOUNT
Every event on CRDF, as it fires
You are seeing 5 of 14 events recorded on CRDF since 2026-05-26.
The five above landed across 3 days. The other 9 were recorded on 2 other days. 8 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CRDF (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 14147L108 · 2026Q2 | $175K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 14147L108 · 2026Q2 | $62K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 14147L108 · 2026Q2 | $37K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 14147L108 · 2026Q2 | $18K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CRDF
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CRDF against its peers
CRDF's operating margin of -8256.3% ranks in the 5th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-04-30.
| Metric | CRDF | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 593000 USD | 7.9M USD | 23 | 10 |
| Gross margin | n/a | 55.3% | n/a | 5 |
| Operating margin | -8256.3% | -76.0% | 5 | 9 |
| Net margin | -7732.0% | -99.6% | 5 | 10 |
| Return on equity | -101.0% | -84.1% | 45 | 18 |
Peers (23): NTRB, PMN, OKYO, RANI, NMRA, ACRV, PDSB, EQ, CRBP, PTHS, MAIA, MNOV, CSBR, MIST, CING, CGTX, SPRO, ATRA, TENX, SMNR, PMVP, HYFT, AURX. Left out: TELO (no annual filing), CNXU (no annual filing). Fiscal periods ending between 2025-03-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (CRDF: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CRDF on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CRDF for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.